4.7 Article

Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity

Related references

Note: Only part of the references are listed.
Article Biochemistry & Molecular Biology

The glycocalyx and immune evasion in cancer

Sina Ghasempour et al.

Summary: In order for tumors to establish malignant lesions, they must first evade detection by immune cells. They do this by modifying their glycocalyx, a network of polysaccharides and glycosylated proteins that prevents immune cells from engulfing them and hides antigens from the immune system. The barriers imposed by the glycocalyx are both physical and linked to immune cell signaling pathways. Therapies have been developed to edit and dismantle the glycocalyx barrier in order to enhance the immune response against tumors.

FEBS JOURNAL (2023)

Review Oncology

Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?

Andrea Aran et al.

Summary: The study of TCR repertoire in cancer patients is important for understanding the anti-tumoural response, predicting prognosis, and determining response to immune checkpoint inhibitor therapies. The TCR repertoire is influenced by various factors and can provide valuable insights for modulating immune responses and predicting outcomes.

CANCERS (2022)

Article Chemistry, Multidisciplinary

Atomic and Specificity Details of Mucin 1 O-Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling

Helena Coelho et al.

Summary: This study uses NMR spectroscopy and molecular modeling techniques to reveal the mechanisms of GalNAc-T2/T3/T4 isoforms in MUC1 O-glycosylation. The experiments show that the lectin domain plays an important role in site selection, and neighboring tandem repeats are critical for subsequent glycosylation. Additionally, specific salt bridges and inverse gamma-turn conformations in MUC1 are found to be key structural motifs for GalNAc-T4 specificity. In-cell analysis also demonstrates that GalNAc-T4 is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo.

JACS AU (2022)

Review Biotechnology & Applied Microbiology

Revisiting the role of CD4+T cells in cancer immunotherapy-new insights into old paradigms

Rong En Tay et al.

Summary: Cancer immunotherapy has transformed cancer treatment, with immune checkpoint blockade therapy and adoptive cell therapy becoming standard care for many cancer types. Recent evidence suggests that CD4(+)T cells play a significant role in the anti-tumour immune response, highlighting their potential importance in cancer immunotherapies.

CANCER GENE THERAPY (2021)

Review Hematology

N-Acetyl Galactosamine Targeting: Paving the Way for Clinical Application of Nucleotide Medicines in Cardiovascular Diseases

Erik A. L. Biessen et al.

Summary: The introduction of N-acetylgalactosamine technology has revolutionized oligonucleotide therapeutics, allowing safe and effective intervention in hepatic targets and even targets previously considered undruggable. This technology has been approved for multiple indications or progressed to clinical trial stages, indicating significant future potential for receptor targeted delivery of gene medicines.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2021)

Article Oncology

Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts

Rachel A. Woolaver et al.

Summary: The study reveals that intrinsic differences in the TCR repertoire of TILs and their different transcriptional trajectories may underlie the heterogeneous antitumor immune responses in different hosts. Antitumor immune responses are highly individualized and different hosts employ different TCR specificities against the same tumors, which may have important implications for developing personalized cancer immunotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Biochemistry & Molecular Biology

Crystal Structure of the Carbohydrate Recognition Domain of the Human Macrophage Galactose C-Type Lectin Bound to GalNAc and the Tumor-Associated Tn Antigen

Adele Gabba et al.

Summary: The MGL protein is an important immunoregulatory receptor that can bind a variety of glycans, with a preference for the glycan GalNAc. New structural studies provide insights into substrate recognition by MGL.

BIOCHEMISTRY (2021)

Review Immunology

Siglec Signaling in the Tumor Microenvironment

Eline J. H. van Houtum et al.

Summary: Siglecs are a family of receptors that recognize sialic acid-containing glycans, expressed on most immune cells and have an important role in the tumor microenvironment. Their signaling pathway in the TME is enhanced through multiple mechanisms favoring tumor immune evasion.

FRONTIERS IN IMMUNOLOGY (2021)

Article Medicine, General & Internal

Tumor vaccination-strategies and time points

Yacine Maringer et al.

Summary: Different strategies of tumor vaccination, their current state of development, the optimal timing and possible combinations of cancer vaccines in the treatment of cancer are discussed. Suitable antigens should be present exclusively on tumor cells and able to induce a specific anti-tumor immune response, i.e. activate cytotoxic and T helper cells. Currently, numerous vaccination approaches as well as combination protocols are being evaluated in clinical trials with the aim to establish specific and low side effect immunotherapies to combat malignancies and enable long-term protection from disease recurrence.

INTERNIST (2021)

Article Multidisciplinary Sciences

Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity

Itziar Ibarlucea-Benitez et al.

Summary: Targeting myeloid receptors Siglec-7 and Siglec-9 shows therapeutic potential in enhancing antitumor immunity, although their effectiveness is influenced by the tumor microenvironment. Development of Fc engineered blocking antibodies against Siglec-7 and Siglec-9 significantly reduces tumor burden, demonstrating their potential as immunotherapy targets.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Chemistry, Multidisciplinary

Sialic Acid Ligands of CD28 Suppress Costimulation of T Cells

Landon J. Edgar et al.

Summary: Sialic acid-containing glycans on the surface of T cells and APCs are alternative ligands of CD28 that compete with CD80 for binding, resulting in attenuated costimulation. Removal of sialic acids enhances antigen-mediated activation of naive T cells and increases revival of effector T cells through synergistic mechanism with PD-1 axis antibody blockade. These findings reveal a previously unrecognized role of sialic acid ligands in attenuation of CD28-mediated costimulation of T cells.

ACS CENTRAL SCIENCE (2021)

Article Immunology

Optimization of Whole Tumor Cell Vaccines by Interaction with Phagocytic Receptors

Mladen Korbelik

Summary: The main function of whole-cell cancer vaccines is the ingestion of tumor antigen-containing material by the patient's antigen-presenting cells. Blocking specific phagocytic receptors may eliminate the therapeutic efficacy of the vaccine, while blocking certain inhibitory receptors could enhance tumor control by the vaccine. This study establishes a potential strategy for enhancing the therapeutic effects of PDT-generated (and possibly other) whole-cell tumor vaccines.

VACCINES (2021)

Review Chemistry, Multidisciplinary

Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation

Hao Cui et al.

Summary: The potential therapeutic application of oligonucleotides that selectively suppress target genes through antisense and RNA interference mechanisms has attracted widespread attention, with a focus on liver-targeted delivery using N-acetylgalactosamine (GalNAc) ligands. Recent progress in the field of GalNAc conjugates for improving cellular uptake and tissue-specific delivery has shown promising results in preclinical and clinical trials.

ACS OMEGA (2021)

Article Nanoscience & Nanotechnology

Sialidase-Conjugated NanoNiche for Efficient Immune Checkpoint Blockade Therapy

Ze-Rui Zhou et al.

Summary: The sialidase-conjugated NanoNiche effectively blocks PD-L1 on tumor cells by recognizing glycosylated PD-L1, leading to enhanced immune cell infiltration and inhibition of tumor cell proliferation. This promising approach shows potential in immune checkpoint blockade therapy.

ACS APPLIED BIO MATERIALS (2021)

Review Oncology

Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion

Suchit Jhunjhunwala et al.

Summary: This review discusses the importance of antigen presentation in the success of immune checkpoint inhibition therapy and mechanisms by which tumors evade immune recognition. Tumors evade immune recognition by modulating antigen expression and altering antigen presentation.

NATURE REVIEWS CANCER (2021)

Review Biochemistry & Molecular Biology

Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses

Heinz Laeubli et al.

CELLULAR AND MOLECULAR LIFE SCIENCES (2020)

Review Immunology

Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment

Stephanie van de Wall et al.

TRENDS IN IMMUNOLOGY (2020)

Article Biochemistry & Molecular Biology

Systemic dysfunction and plasticity of the immune macroenvironment in cancer models

Breanna M. Allen et al.

NATURE MEDICINE (2020)

Article Biochemistry & Molecular Biology

Targeted glycan degradation potentiates the anticancer immune response in vivo

Melissa A. Gray et al.

NATURE CHEMICAL BIOLOGY (2020)

Article Biochemistry & Molecular Biology

Clonal replacement of tumor-specific T cells following PD-1 blockade

Kathryn E. Yost et al.

NATURE MEDICINE (2019)

Review Pharmacology & Pharmacy

The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity

Anne Barenwaldt et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2019)

Article Medicine, Research & Experimental

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells

Michal A. Stanczak et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

Article Biochemistry & Molecular Biology

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Moshe Sade-Feldman et al.

Article Oncology

CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8(+) T Cells

Fernando P. Canale et al.

CANCER RESEARCH (2018)

Article Cell Biology

Metabolic sialic acid blockade lowers the activation threshold of moDCs for TLR stimulation

Christian Bull et al.

IMMUNOLOGY AND CELL BIOLOGY (2017)

Review Biochemistry & Molecular Biology

The direct and indirect effects of glycans on immune function

Linda G. Baum et al.

GLYCOBIOLOGY (2017)

Review Biochemistry & Molecular Biology

Sialic acids in cancer biology and immunity

Oliver M. T. Pearce et al.

GLYCOBIOLOGY (2016)

Article Multidisciplinary Sciences

Precision glycocalyx editing as a strategy for cancer immunotherapy

Han Xiao et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)

Article Multidisciplinary Sciences

Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells

Maurizio Perdicchio et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)

Article Urology & Nephrology

Increased expression of MUC1 and sialyl Lewis antigens in different areas of clear renal cell carcinoma

Malgorzata Borzym-Kluczyk et al.

CLINICAL AND EXPERIMENTAL NEPHROLOGY (2015)

Review Oncology

Sialic Acids Sweeten a Tumor's Life

Christian Bull et al.

CANCER RESEARCH (2014)

Article Medicine, Research & Experimental

Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance

Camilla Jandus et al.

JOURNAL OF CLINICAL INVESTIGATION (2014)

Article Biochemistry & Molecular Biology

Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion

Jason E. Hudak et al.

NATURE CHEMICAL BIOLOGY (2014)

Review Biochemistry & Molecular Biology

Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation

Yvette van Kooyk et al.

MOLECULAR IMMUNOLOGY (2013)

Review Immunology

Molecular mechanisms of T cell co-stimulation and co-inhibition

Lieping Chen et al.

NATURE REVIEWS IMMUNOLOGY (2013)

Article Biochemistry & Molecular Biology

Multifarious roles of sialic acids in immunity

Ajit Varki et al.

GLYCOBIOLOGY OF THE IMMUNE RESPONSE (2012)

Article Immunology

Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation

Chiara Napoletano et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2012)

Review Oncology

Whole Cell Vaccines-Past Progress and Future Strategies

Bridget P. Keenan et al.

SEMINARS IN ONCOLOGY (2012)

Article Biochemistry & Molecular Biology

Immunomodulation of monocyte-derived dendrite cells through ligation of tumor-produced mucins to Siglec-9

Mariko Ohta et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)

Review Pathology

Alterations in glycosylation as biomarkers for cancer detection

Celso A. Reis et al.

JOURNAL OF CLINICAL PATHOLOGY (2010)

Article Biochemistry & Molecular Biology

Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes

Jennifer A. Belisle et al.

MOLECULAR CANCER (2010)

Review Immunology

Functional implications of T cell receptor diversity

Stephen J. Turner et al.

CURRENT OPINION IN IMMUNOLOGY (2009)

Article Biochemistry & Molecular Biology

C-type lectins on dendritic cells: key modulators for the induction of immune responses

Yvette van Kooyk

BIOCHEMICAL SOCIETY TRANSACTIONS (2008)

Article Biochemistry & Molecular Biology

IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis

Xavier Brochet et al.

NUCLEIC ACIDS RESEARCH (2008)

Review Immunology

Mammalian glycosylation in immunity

Jamey D. Marth et al.

NATURE REVIEWS IMMUNOLOGY (2008)

Review Immunology

Siglecs and their roles in the immune system

Paul R. Crocker et al.

NATURE REVIEWS IMMUNOLOGY (2007)

Article Biochemistry & Molecular Biology

Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes

JQ Zhang et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2000)